NO20091809L - Pharmaceutical material of entinylestradiol and drospirenone for use as a contraceptive - Google Patents

Pharmaceutical material of entinylestradiol and drospirenone for use as a contraceptive

Info

Publication number
NO20091809L
NO20091809L NO20091809A NO20091809A NO20091809L NO 20091809 L NO20091809 L NO 20091809L NO 20091809 A NO20091809 A NO 20091809A NO 20091809 A NO20091809 A NO 20091809A NO 20091809 L NO20091809 L NO 20091809L
Authority
NO
Norway
Prior art keywords
daily dosage
drospirenone
dosage units
ethinylestradiol
approx
Prior art date
Application number
NO20091809A
Other languages
Norwegian (no)
Inventor
Wolfgang Heil
Ralph Lipp
Renate Heithecker
Juergen Hilmann
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091809(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2000/001213 external-priority patent/WO2001015701A1/en
Publication of NO20091809L publication Critical patent/NO20091809L/en
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Priority to NO20091809A priority Critical patent/NO20091809L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det beskrives farmasøytiske materialer som omfatter som et første aktive 6?,7?,15?? 16?-dimetylen-3-okso-17?-pregn-4-en-21,17-karbolakton (drospirenon) i en mengde korresponderende til en daglig dosering, ved administrering av materialet, fra ca. 2 mg til ca. 4 mg, og som et andre aktive middel 17 ?-etinylestradiol (etinylestradiol) i en mengde korresponderende til daglig dosering av fra ca. 0,01 mg til ca. 0,05 mg, sammen med eller flere farmasøytisk akseptable bærere eller eksipienter. I en spesifikk utførelse omfatter materialet et antall separat pakkede og individuelt fjern-bare daglige doseringsenheter plassert i en pakningsenhet og tiltenkt for oral administrering på minst 21 påfølgende dager, hvorpå nevnte daglige doseringsenheter omfatter kombinasjonen av drospirenon og etinylestrediol. Materialet kan videre omfatte 7 eller mindre daglige doseringsenheter som inneholder intet aktivt middel, eller som kun inneholder etinylestradiol.Pharmaceutical materials are described which comprise as a first active 6 ?, 7 ?, 15 ?? 16? -Dimethylene-3-oxo-17? -Pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, upon administration of the material, from about 2 mg to approx. 4 mg, and as a second active agent 17β-ethinylestradiol (ethinylestradiol) in an amount corresponding to daily dosage of from ca. 0.01 mg to approx. 0.05 mg, together with or more pharmaceutically acceptable carriers or excipients. In one specific embodiment, the material comprises a plurality of separately packaged and individually removable daily dosage units placed in a packing unit and intended for oral administration of at least 21 consecutive days, said daily dosage units comprising the combination of drospirenone and ethinyl estrediol. The material may further comprise 7 or less daily dosage units containing no active agent or containing only ethinyl estradiol.

NO20091809A 1999-08-31 2009-05-07 Pharmaceutical material of entinylestradiol and drospirenone for use as a contraceptive NO20091809L (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20091809A NO20091809L (en) 1999-08-31 2009-05-07 Pharmaceutical material of entinylestradiol and drospirenone for use as a contraceptive

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24095399P 1999-08-31 1999-08-31
EP99202826 1999-08-31
PCT/IB2000/001213 WO2001015701A1 (en) 1999-08-31 2000-08-31 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
NO20020801A NO326860B1 (en) 1999-08-31 2002-02-19 Pharmaceutical composition of ethinylostradiol and drospirenone for use as a contraceptive
NO20091809A NO20091809L (en) 1999-08-31 2009-05-07 Pharmaceutical material of entinylestradiol and drospirenone for use as a contraceptive

Publications (1)

Publication Number Publication Date
NO20091809L true NO20091809L (en) 2002-04-26

Family

ID=26153358

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20083854A NO327588B3 (en) 1999-08-31 2008-09-08 Pharmaceutical composition and composition comprising ethinylostradiol and drospirenone for use as a contraceptive
NO20091809A NO20091809L (en) 1999-08-31 2009-05-07 Pharmaceutical material of entinylestradiol and drospirenone for use as a contraceptive
NO2010004C NO2010004I1 (en) 1999-08-31 2010-02-26 0.02 mg of ethinylostradiol (as betadexclathrate) and 3mg drospirenone

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20083854A NO327588B3 (en) 1999-08-31 2008-09-08 Pharmaceutical composition and composition comprising ethinylostradiol and drospirenone for use as a contraceptive

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2010004C NO2010004I1 (en) 1999-08-31 2010-02-26 0.02 mg of ethinylostradiol (as betadexclathrate) and 3mg drospirenone

Country Status (11)

Country Link
CN (1) CN1223350C (en)
BG (2) BG109749A (en)
CA (1) CA2382426C (en)
EE (1) EE05317B1 (en)
HR (1) HRP20020258B1 (en)
IL (2) IL197396A (en)
MX (1) MXPA02002043A (en)
NO (3) NO327588B3 (en)
RU (4) RU2269342C2 (en)
SK (1) SK287634B6 (en)
UA (1) UA81387C2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
CN101489563A (en) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 Pharmaceutical preparations for contraception and for preventing the risk of congenital malformations
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (en) 2011-11-23 2021-09-30 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
RU2618471C2 (en) * 2012-12-03 2017-05-03 Закрытое Акционерное Общество "Вертекс" Oral pharmaceutical composition of diuretics and ace inhibitor in micronized form, drug and its application
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (en) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. NATURAL COMBINED HORMONE SUBSTITUTION COMPOSITIONS AND THERAPIES
CN108606963B (en) * 2017-12-27 2021-05-18 上海长海医院 Compound contraceptive patch containing drospirenone and estrogen, preparation method and application
CN111529482A (en) * 2020-05-20 2020-08-14 祝培 Testosterone undecanoate sustained-release implant and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (en) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-methylene-spirolactones, processes for their preparation and pharmaceuticals containing them
DE4344462C2 (en) * 1993-12-22 1996-02-01 Schering Ag Composition for contraception
DE4411585A1 (en) * 1994-03-30 1995-10-05 Schering Ag Combined pharmaceutical preparation for hormonal contraception
WO1998004269A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen

Also Published As

Publication number Publication date
RU2449796C9 (en) 2007-10-27
NO327588B1 (en) 2009-08-31
EE05317B1 (en) 2010-08-16
RU2449796C2 (en) 2006-02-10
IL197396A (en) 2010-04-29
RU2482853C2 (en) 2013-05-27
RU2010114825A (en) 2011-10-20
BG65204B1 (en) 2007-07-31
IL200482A0 (en) 2011-07-31
BG109749A (en) 2008-06-30
CA2382426C (en) 2006-02-28
CN1407895A (en) 2003-04-02
NO2010004I1 (en) 2010-03-22
UA81387C2 (en) 2008-01-10
RU2269342C9 (en) 2007-10-27
HRP20020258A2 (en) 2005-02-28
RU2396082C2 (en) 2010-08-10
MXPA02002043A (en) 2003-08-20
CN1223350C (en) 2005-10-19
RU2005131868A (en) 2007-04-20
HRP20020258B1 (en) 2007-05-31
BG106533A (en) 2002-10-31
NO20083854L (en) 2002-04-26
SK2572002A3 (en) 2002-11-06
NO327588B3 (en) 2011-05-16
SK287634B6 (en) 2011-04-05
RU2269342C2 (en) 2006-02-10
CA2382426A1 (en) 2001-03-08
EE200900049A (en) 2009-10-15

Similar Documents

Publication Publication Date Title
NO20020801L (en) Pharmaceutical material of ethinylestradiol and drospirenone for use as a contraceptive
NO327588B1 (en) Pharmaceutical composition and composition comprising ethinylostradiol and drospirenone for use as a contraceptive
BG66095B1 (en) Pregelatinized starch in a controlled release preparation
KR960706344A (en) MEANS AND METHOD FOR HORMONAL CONTRACEPTION AND / OR THE TREATMENT OF ACNE
NO20011471L (en) New oral sustained release formulations
CO5251419A1 (en) NANOPARTICULATED COMPOSITIONS OF EPLERENONA
CA2385890A1 (en) Controlled release compositions comprising nimesulide
UA41401C2 (en) Pharmaceutical combined contraceptive agent
CY1108265T1 (en) STRONG INTERMEDIATE PHARMACEUTICAL FORM FOR CONTRACT
KR970706004A (en) Hormonal Drugs and Their Use for the Treatment of Estrogen Deficiency (NOVEL HORMONAL MEDICAMENTS AND USE THEREOF FOR CORRECTING OESTROGEN DEFICIENCIES)
KR890009407A (en) Pharmaceutical dosage unit for the treatment of menopause and osteoporosis
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
NO20072687L (en) Pharmaceutical contraceptive preparation
JO2213B1 (en) A pharmaceutical composition for use as a contraceptive
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
TW200638951A (en) Solid oral pharmaceutical form for contraception
ECSP003721A (en) A PHARMACEUTICAL COMPOSITION TO BE USED AS AN CONTRACEPTIVE
EP2305267A3 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
HRP20020666B1 (en) DROSPIRENON FOR HORMONAL REPLACEMENT THERAPY
UY29378A1 (en) PHARMACEUTICAL PREPARATION FOR ORAL ANTI-CONCEPTION

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application